Jazz Pharmaceuticals Raises Outlook as Record Revenue Masks Quarterly Loss
Jazz Pharmaceuticals delivered record Q3 revenue, raised its full-year outlook and posted a sizeable net loss—fueling debate over valuation and earnin…
Pasithea Shares Rise After FDA Clears PAS-004 for Phase 2 NF1 Tumor Study
FDA clearance of Pasithea’s PAS-004 IND creates a regulatory catalyst as traders focus on the planned Phase 2 NF1 tumor study.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
BioNTech’s Q3 Update Puts Pipeline Progress and Revenue Diversification in Focus
BioNTech’s Q3 2026 update keeps attention on pipeline progress, potential catalysts and the effort to diversify beyond p…
Pfizer Raises 2026 Guidance After Strong Third-Quarter Results
Pfizer’s strong Q3 2026 results and raised full-year guidance provide a constructive signal on earnings momentum heading…
Waters’ MOBILion Acquisition Signals Continued Consolidation in Life-Sciences Tools
Waters’ planned MOBILion acquisition could broaden its analytical-instrumentation portfolio and reinforce its role in ph…
Bright Minds Biosciences Stock Plunges 52% After FDA Places Epilepsy Trial on Hold
Bright Minds Biosciences shares fell as much as 52% after the FDA placed its BMB-101 epilepsy trial on clinical hold.
Lupin Wins US FDA Approval for Amifampridine Tablets
Lupin’s November 2 FDA approval for amifampridine adds a potential rare-disease growth catalyst, though commercial impac…
Karyopharm Bankruptcy and Ayrmid Merger Put Pharma Restructuring in Focus
Karyopharm’s bankruptcy protection filing and planned merger with Ayrmid highlight the growing role of restructuring-dri…
Axsome’s Q3 Update Gives AXSM Investors a Read on CNS Commercial Execution
Axsome’s third-quarter update gives AXSM investors a results-day lens on CNS commercial execution, pipeline momentum and…
uniQure’s QURE Shares Enter the Spotlight After FDA Grants Huntington’s Gene-Therapy Priority Review
FDA acceptance and Priority Review for uniQure’s Huntington’s gene-therapy application create a potentially important ca…
Karyopharm Bankruptcy and Ayrmid Merger Put Shareholder Recovery in Focus
Karyopharm’s bankruptcy filing and planned Ayrmid merger highlight creditor priority and uncertainty over any recovery f…